US Patent Issued to Shandong Boan Biotechnology on Feb. 10 for "Optimized anti-CD3 arm in the generation of t-cell bispecific antibodies for immunotherapy" (American, German Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,545,730, issued on Feb. 10, was assigned to Shandong Boan Biotechnology Co. Ltd. (Yantai, China).

"Optimized anti-CD3 arm in the generation of t-cell bispecific antibodies for immunotherapy" was invented by Avanish Varshney (Woburn, Mass.), Li Zhou (Woburn, Mass.) and Irene Schneider (Hanau, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides novel CD3 antigen binding fragments with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency, remaining tumor cell killing and reduced toxicity. The present inventi...